Johnson Pharmacare has announced the publication of its financial results for the quarter ended June 30, 2026. The company's Board of Directors approved these results.

For this quarter, the company reported nil total income from operations.

It recorded a net loss after tax of 1.10 Cr, with basic and diluted earnings per share at (0.02). The paid-up equity share capital stands at 55.00 Cr.

These results offer stakeholders an update on the company's financial performance.